

Regulus Therapeutics Inc.
Form DEFA14A
April 30, 2015

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No.)

Filed by the Registrant

Filed by a party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Pursuant to §240.14a-12

Regulus Therapeutics Inc.

(Name of Registrant as Specified In Its Charter)

N/A

(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

.. Fee paid previously with preliminary materials.

.. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

(2) Form, Schedule or Registration Statement No.:

(3) Filing Party:

(4) Date Filed:

***** Exercise Your *Right* to Vote *****

**Important Notice Regarding the Availability of Proxy Materials for the
Shareholder Meeting to Be Held on June 10, 2015.**

REGULUS THERAPEUTICS INC.

Meeting Information

Meeting Type: Annual Meeting
For holders as of: April 20, 2015
Date: June 10, 2015 **Time:** 9:00 AM PDT
Location: Regulus Therapeutics Inc.
3545 John Hopkins Ct., Suite 210

San Diego, CA 92121

You are receiving this communication because you hold shares in the company named above.

This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).

We encourage you to access and review all of the important information contained in the proxy materials before voting.

See the reverse side of this notice to obtain proxy materials and voting instructions.

M91771-P63684

Edgar Filing: Regulus Therapeutics Inc. - Form DEFA14A

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow (located on the following page) available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a voting instruction form.

M91772-P63684

Voting Items

The Board of Directors recommends you vote

FOR the following:

1. Election of Directors

Nominees:

- | | |
|---------------------------------|-----------------------------------|
| 01) David Baltimore, Ph.D. | 05) William Rastetter, Ph.D. |
| 02) Bruce Carter, Ph.D. | 06) Douglas Williams, Ph.D. |
| 03) Mark Foletta | 07) Kleanthis Xanthopoulos, Ph.D. |
| 04) Stelios Papadopoulos, Ph.D. | |

The Board of Directors recommends you vote FOR the following proposal:

2. Ratification of the selection of Ernst & Young LLP as the independent registered public accounting firm of the company for the year ending December 31, 2015.

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.
M91773-P63684

Voting Instructions

M91774-P63166